In 2019, given the challenges of accelerated COVID-19 vaccine development and threats to scientific integrity, we stood up COVAT, the COvid Vaccine Analysis Team, hosted by Georgetown University, to provide independent analysis of emerging data on COVID vaccines.

COVAT members brought deep and broad scientific leadership experience with vaccines, including from government, industry, and academia.

COVAT held >50 informal briefings and Q and A sessions with journalists, providing access to diverse expertise and opinions.

COVAT also shared facts and perspectives through other channels, such as scientific publications and webinars.

In 2025, amidst increasing misinformation and mistrust of vaccines, and new threats to the availability and reliability of governmental information, COVAT became E-VAT: providing facts and rapid analysis on emerging vaccine and outbreak issues.